Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05604937 |
| Other study ID # |
ZYunfan |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
February 2, 2023 |
| Est. completion date |
December 2024 |
Study information
| Verified date |
March 2023 |
| Source |
ShuGuang Hospital |
| Contact |
Wei'an Yuan, Chief |
| Phone |
0086-021-20256630 |
| Email |
weian_1980[@]163.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This is a randomized, controlled, multi-center clinical trail to objectively evaluate safety
and efficacy of shi's traumatology Osteopathic manipulative treatment for cervicogenic
dizziness. Multi-center study is planned to be carried out in 4 medical institutions in
Shanghai, including Shuguang Hospital Affiliated to Shanghai University of Traditional
Chinese Medicine, Yueyang traditional chinese and western medicine Hospital Affiliated to
Shanghai University of Traditional Chinese Medicine, Baoshan traditional chinese and western
medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and
Shanghai General Hospital. Randomly Assigned 106 patients (18 < ages <65 ) who meet the
diagnostic criteria of cervicogenic dizziness to the treatment group and the control group by
a ratio of 1:1, using betahistine mesylate tablets as positive control. Observe and compare
the variations of Dizziness Handicap Inventory (DHI) from baseline in two groups after 2
weeks treatment, using Dizziness Handicap Inventory (DHI) as the main efficacy index. After
the end of treatment, performing 4weeks follow-up, focus to compare the recurrence rate of
vertigo symptoms in the period of 4weeks follow-up after 2 weeks treatment. The safety
indexes will be observed and compared, including vital sign, physical examination and adverse
event, in the trail.
The electronic case Report Form (eCRF) will be used to collect and manage the study data.
The data of the primary efficacy index, DHI, patient's vertigo condition report, both use
electronic patient-reported outcome (e-PRO) to collect. To ensure quality of study, this
trail intends to set safeguard measures for clinical trail including setting Clinical
Research Associate (CRA) to monitor study quality, evaluating efficacy by the third person,
training manual therapy physicians, make access and regular and irregular assessment
consistent.
Description:
Recruitment Participants will be recruited from outpatients of Shuguang Hospital Affiliated
to Shanghai University of Traditional Chinese Medicine, Yueyang traditional chinese and
western medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,
Baoshan traditional chinese and western medicine Hospital Affiliated to Shanghai University
of Traditional Chinese Medicine, and Shanghai General Hospital. Researcher will provide both
oral and written information about the trial to patients, and explain detailed information
about participating in the trail, including interventions, procedures and potential adverse
reactions. Written informed consent will be obtained from all participants prior to their
participation. Researcher will protect the confidentiality of the participants by keeping
anonymous state. Documents that have the identity participants will be kept strictly
confidential. The researchers in each clinical trail center should take responsibility for
medical treatment of patients and make medical decisions related to clinical trail. Ensure
patients can receive effective treatment for their diseases during the clinical period or
when adverse events happen.
Data management The electronic case Report Form (eCRF) will be used to collect and manage
data of this trial. The primary and secondary outcomes will be collected by the eCRF.
Electronic Data Capture Data collection and Management
- CRF: CRF will be designed by data manager according to the protocol, and set up data
validation rules, according to Data Validation Plan. It will be used after passing the
test and being approved by sponsor.
- Data Entry: CRF data are derived from original records. Data entry personnel enter visit
data of patients into Electronic Data Capture (EDC) in time, according to instructions.
- Source Data Verification (SDV): The monitor performs source data verification (SDV) to
check the consistency of CRF data and source data. Issue if there has questions.
- Data Questions and Answers: Questions come from EDC logical verification system
questions, auditors, data managers and other manual questions. Researchers need to
timely answer questions. The data manager and the monitor will reply to the question,
and may issue the question again if necessary, until the data is "clean".
- Researcher Signature: After data entering and SDV, researchers use electronic signature
to review and confirm data. If data should be modified after the signature, researchers
need to sign the signature again.
- Database Locking: Database locking will be signed by the main researchers, sponsor,
statistical analyst and data manager. The data manager locks the database.
- Database Submitting: Database will be submitted to statistical analyst by data manager.
- CRF Archiving: Each patient's CRF will generate as a PDF electronic document for
preservation
- Data Management Report: Data manager write reports of data management.
- EDC Shutdown: Data manager will shut down the database after statistical analysis
completed.
External data transmission Sign external data transmission protocol and manage external data
according to DMP.
Medical code Adverse events will use ICH M1: Medical Dictionary of Regulatory Activities
(MedDRA) (Version 21.0 or above) to code. Drug combination use WHO ATC to classify.
Sample Size Calculation In summary of previous research reports, the effective rate of
Betahistine Mesilate Tablets to vertigo patients is 60.1%. In this trail, the effective rate
of the experimental group after manual therapy will be set to 85%.
Known：P1=60.1%，P2=85%，let α=0.05，β=0.20. Follow the sample size calculation formula required
for completely randomized design two population rates hypothesis test to estimate. It was
calculated that 47.99≈48 cases need to be observed in each group. If there are 10% to drop
out, 53 patients should be included. Two groups need a total of 106 patients.
Statistical Analysis The statistical analysis will be carried out using SAS9.4 software.
Except validity test uses one-side test. All of other statistical tests use a two-sided test.
P < 0.05 is considered statistically significant. The primary efficacy index will be analyzed
based on Intention-to-Test (ITT) and Per-Protocol set (PPS). ITT is defined as the group of
patients that were randomized and had at least one treatment, and obtained the efficacy date.
PPS is defined as a subset of ITT, except for incomplete drug treatment, major protocol
deviation, lack of key effectiveness indexes, and other situations that are judged by blind
review meeting to have a significant impact on efficacy evaluation. Main analysis model aim
to analyze the variation of Vss-c score relative baseline after 2 weeks of treatment. The
variation of Vss-c score relative baseline is as dependent variable, included in the baseline
level for correction, and Give the overall comparison p value. Disappearing and happening
time of vertigo symptom, with normal distribution, will be analyzed by independent-sample
t-test. Chi-square test will be performed to analyze recurrence rate of vertigo symptom
within 4 weeks of follow-up after treatment. Baseline data and descriptive statistical
demographic data will calculate cases, mean, standard deviation, quartile, minimum and
maximum values will be calculated for continuous variables, frequency and constituent ratio
for count and grade data. Safety analysis is performed based on safety set (SS), which is
defined as the group of patients who received treatment at least once and collected safety
date. Adverse events will be coded according to the ICH International Medical Dictionary for
Regulatory Activities (MedDRA). The frequency and incidence of adverse events/reactions,
serious adverse events/reactions, and adverse events/reactions leading to shedding during
treatment were calculated. Compliance analysis will be performed to calculate the percentage
of compliance of patients with treatment and medication in the range of 80% to 120%. Missing
date based on ITT primary efficacy indexes analysis is imputed by using LOCF method, and
provide analysis results not carried forward. Other analyses are performed by using analysis
results not carried forward.
